Oral supplementation with omega-3 fatty acids and inflammation markers in patients with chronic kidney disease in hemodialysis.
What this study found
Omega-3 supplementation lowered inflammatory markers over 12 weeks and outperformed control on the post-treatment comparison. In the omega-3 group, CRP fell from 14.9 (3.1) to 10.9 (2.8) mg/L, IL-6 from 72.9 (24.4) to 53.9 (14.9) mg/mL, and TNF-α from 67.0 (13.9) to 58.2 (12.4) mg/mL, with within-group P<0.001, <0.001, and 0.002, respectively. The IL-10/IL-6 ratio increased from 1.80 (0.87) to 2.55 (1.13) (P<0.001), while IL-10 and IL-10/TNF-α did not change significantly (P=0.27 and P=0.12). After 12 weeks, between-group differences were significant at P<0.05, and the control group showed…
- Study & population
- Randomized, double-blind trial in adults with chronic kidney disease on maintenance hemodialysis in Maracaibo, Venezuela.
- Intervention
- Oral omega-3 fatty acid supplementation was given as four capsules daily for 12 weeks.
- Key limitation
- The intervention was short, lasting only 12 weeks, and the analysis was limited by attrition, with 10 participants excluded from the omega-3 arm and 9 from the control arm.
View source
Open PDFOriginal abstract
Chronic kidney disease (CKD) is an increasingly common public health problem that increases the risk of death due to cardiovascular complications by 2-3 times compared to the general population. This research concerns a prospective, randomized, double-blind study in patients with CKD undergoing hemodialysis. The participants were assigned to one of two groups: the study group (group A; 46 patients) received four capsules (2.4 g) of omega-3 fatty acids daily during the 12-week intervention, while patients in the control group (group B; 47 patients) received four capsules of paraffin oil. The patients' general characteristics, nutritional indicators, renal disease markers and inflammatory markers (C-reactive protein, interleukin-6, interleukin-10 and tumour necrosis factor alpha) were evaluated. No differences were found between the general characteristics of the patients (P <0.05), and no differences were shown in the nutritional indicators and markers of kidney disease (P <0.05). Patients in group A showed significant decreases in levels of C-reactive protein, interleukin-6, tumour necrosis factor alpha and the interleukin-10/interleukin-6 ratio after 12 weeks of supplementation (P <0.05). Patients in group B did not show any significant changes in concentrations of inflammatory markers during the intervention (P <0.05). In conclusion, oral supplementation with omega-3 fatty acids produces a significant decrease in the concentrations of inflammation markers in patients with chronic kidney disease on hemodialysis. Novelty bullets: ●Oral supplementation with omega-3 fatty acids produced significant decreases in the concentrations of inflammation markers. ●This supplementation could be given to patients with uremic syndrome and coronary heart disease to reduce cardiovascular risk.